STOCK TITAN

[Form 4] SELECT MEDICAL HOLDINGS CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 highlights for SELECT MEDICAL HOLDINGS CORP (SEM): Executive Vice President Martin F. Jackson was granted 150,000 shares of SEM common stock on 07/29/2025. The shares are restricted stock that will vest in three equal annual tranches (per the footnote) and were issued at a stated price of $0, indicating an equity incentive rather than an open-market purchase.

Following the award, Jackson now holds 1,412,881 shares directly. In addition, he reports 10,536 shares held indirectly for the benefit of his children, which he disclaims except for any pecuniary interest.

No derivative securities were reported in Table II and no sales occurred, so the transaction is purely an equity grant. The filing signals continued insider alignment with shareholders but entails a small incremental dilution to existing owners.

Punti salienti del Modulo 4 per SELECT MEDICAL HOLDINGS CORP (SEM): Il Vice Presidente Esecutivo Martin F. Jackson ha ricevuto 150.000 azioni ordinarie SEM il 29/07/2025. Le azioni sono azioni vincolate che matureranno in tre tranche annuali uguali (come indicato nella nota a piè di pagina) e sono state emesse a un prezzo nominale di 0$, indicando un incentivo azionario piuttosto che un acquisto sul mercato aperto.

Dopo l'assegnazione, Jackson detiene ora 1.412.881 azioni direttamente. Inoltre, segnala 10.536 azioni detenute indirettamente a beneficio dei suoi figli, delle quali rinuncia tranne che per eventuali interessi pecuniari.

Non sono stati riportati titoli derivati nella Tabella II e non sono state effettuate vendite, quindi la transazione rappresenta esclusivamente una concessione azionaria. La comunicazione indica un continuo allineamento degli insider con gli azionisti, pur comportando una piccola diluizione incrementale per gli attuali proprietari.

Aspectos destacados del Formulario 4 para SELECT MEDICAL HOLDINGS CORP (SEM): El Vicepresidente Ejecutivo Martin F. Jackson recibió 150,000 acciones ordinarias de SEM el 29/07/2025. Las acciones son acciones restringidas que se consolidarán en tres partes iguales anuales (según la nota al pie) y se emitieron a un precio declarado de $0, lo que indica un incentivo de capital en lugar de una compra en el mercado abierto.

Tras la adjudicación, Jackson posee ahora 1,412,881 acciones directamente. Además, informa de 10,536 acciones mantenidas indirectamente para beneficio de sus hijos, de las cuales renuncia salvo por cualquier interés pecuniario.

No se reportaron valores derivados en la Tabla II y no se realizaron ventas, por lo que la transacción es únicamente una concesión de acciones. La presentación señala una continua alineación de los insiders con los accionistas, aunque implica una pequeña dilución incremental para los propietarios existentes.

SELECT MEDICAL HOLDINGS CORP (SEM)의 Form 4 주요 내용: 부사장 Martin F. Jackson이 2025년 7월 29일에 SEM 보통주 150,000주를 부여받았습니다. 이 주식은 3년에 걸쳐 동일한 비율로 나누어 베스팅되는 제한 주식이며(각주 참고), 명시된 가격은 0달러로, 이는 공개 시장에서의 매수가 아닌 주식 인센티브임을 나타냅니다.

수여 후 Jackson은 현재 직접 1,412,881주를 보유하고 있습니다. 또한, 자녀들을 위해 간접적으로 10,536주를 보유하고 있으며, 금전적 이익을 제외하고는 이를 포기한다고 보고합니다.

표 II에 파생 증권은 보고되지 않았고 매도도 없었으므로, 이 거래는 순수한 주식 부여입니다. 이 보고는 내부자와 주주 간의 지속적인 일치를 나타내지만 기존 소유자에게는 소량의 희석 효과가 있습니다.

Points clés du Formulaire 4 pour SELECT MEDICAL HOLDINGS CORP (SEM) : Le Vice-Président Exécutif Martin F. Jackson s'est vu attribuer 150 000 actions ordinaires SEM le 29/07/2025. Ces actions sont des actions restreintes qui seront acquises en trois tranches annuelles égales (selon la note de bas de page) et ont été émises à un prix déclaré de 0 $, indiquant une incitation en actions plutôt qu'un achat sur le marché libre.

Suite à cette attribution, Jackson détient désormais 1 412 881 actions en direct. De plus, il déclare 10 536 actions détenues indirectement au bénéfice de ses enfants, dont il décline la propriété sauf pour tout intérêt pécuniaire.

Aucun titre dérivé n'a été déclaré dans le Tableau II et aucune vente n'a eu lieu, ce qui fait de cette opération une simple attribution d'actions. Ce dépôt signale un alignement continu des initiés avec les actionnaires, mais entraîne une légère dilution supplémentaire pour les propriétaires existants.

Formular 4 Highlights für SELECT MEDICAL HOLDINGS CORP (SEM): Der Executive Vice President Martin F. Jackson erhielt am 29.07.2025 150.000 Aktien der SEM-Stammaktien. Die Aktien sind eingeschränkte Aktien, die in drei gleichen jährlichen Tranchen (laut Fußnote) freigegeben werden und zu einem angegebenen Preis von 0$ ausgegeben wurden, was auf einen Aktienanreiz und nicht auf einen Kauf am offenen Markt hinweist.

Nach der Zuteilung hält Jackson nun 1.412.881 Aktien direkt. Zusätzlich meldet er 10.536 Aktien, die indirekt zugunsten seiner Kinder gehalten werden, für die er außer einem finanziellen Interesse auf die Verfügungsgewalt verzichtet.

In Tabelle II wurden keine derivativen Wertpapiere gemeldet und es fanden keine Verkäufe statt, sodass die Transaktion ausschließlich eine Aktienzuteilung darstellt. Die Meldung signalisiert eine weiterhin enge Ausrichtung der Insider mit den Aktionären, bringt jedoch eine geringe zusätzliche Verwässerung für die bestehenden Eigentümer mit sich.

Positive
  • Enhanced management alignment: 150,000-share restricted grant ties EVP compensation to future share performance.
  • No insider selling: Filing records only an award; absence of sales avoids negative sentiment.
Negative
  • Slight dilution: New share issuance marginally increases SEM’s outstanding shares, though the impact appears minor.

Insights

TL;DR: Insider receives 150k restricted shares; boosts alignment, minimal immediate dilution.

The grant increases Jackson’s direct stake to >1.4 million shares, reinforcing long-term incentives because shares vest over three years. No cash outlay or sales were recorded, so the transaction is not a valuation signal but rather part of executive compensation. While any new issuance is dilutive, 150k shares is modest for a company of SEM’s size and unlikely to affect per-share metrics materially. Overall impact on valuation is neutral; insider ownership rise is a mild positive for governance.

Punti salienti del Modulo 4 per SELECT MEDICAL HOLDINGS CORP (SEM): Il Vice Presidente Esecutivo Martin F. Jackson ha ricevuto 150.000 azioni ordinarie SEM il 29/07/2025. Le azioni sono azioni vincolate che matureranno in tre tranche annuali uguali (come indicato nella nota a piè di pagina) e sono state emesse a un prezzo nominale di 0$, indicando un incentivo azionario piuttosto che un acquisto sul mercato aperto.

Dopo l'assegnazione, Jackson detiene ora 1.412.881 azioni direttamente. Inoltre, segnala 10.536 azioni detenute indirettamente a beneficio dei suoi figli, delle quali rinuncia tranne che per eventuali interessi pecuniari.

Non sono stati riportati titoli derivati nella Tabella II e non sono state effettuate vendite, quindi la transazione rappresenta esclusivamente una concessione azionaria. La comunicazione indica un continuo allineamento degli insider con gli azionisti, pur comportando una piccola diluizione incrementale per gli attuali proprietari.

Aspectos destacados del Formulario 4 para SELECT MEDICAL HOLDINGS CORP (SEM): El Vicepresidente Ejecutivo Martin F. Jackson recibió 150,000 acciones ordinarias de SEM el 29/07/2025. Las acciones son acciones restringidas que se consolidarán en tres partes iguales anuales (según la nota al pie) y se emitieron a un precio declarado de $0, lo que indica un incentivo de capital en lugar de una compra en el mercado abierto.

Tras la adjudicación, Jackson posee ahora 1,412,881 acciones directamente. Además, informa de 10,536 acciones mantenidas indirectamente para beneficio de sus hijos, de las cuales renuncia salvo por cualquier interés pecuniario.

No se reportaron valores derivados en la Tabla II y no se realizaron ventas, por lo que la transacción es únicamente una concesión de acciones. La presentación señala una continua alineación de los insiders con los accionistas, aunque implica una pequeña dilución incremental para los propietarios existentes.

SELECT MEDICAL HOLDINGS CORP (SEM)의 Form 4 주요 내용: 부사장 Martin F. Jackson이 2025년 7월 29일에 SEM 보통주 150,000주를 부여받았습니다. 이 주식은 3년에 걸쳐 동일한 비율로 나누어 베스팅되는 제한 주식이며(각주 참고), 명시된 가격은 0달러로, 이는 공개 시장에서의 매수가 아닌 주식 인센티브임을 나타냅니다.

수여 후 Jackson은 현재 직접 1,412,881주를 보유하고 있습니다. 또한, 자녀들을 위해 간접적으로 10,536주를 보유하고 있으며, 금전적 이익을 제외하고는 이를 포기한다고 보고합니다.

표 II에 파생 증권은 보고되지 않았고 매도도 없었으므로, 이 거래는 순수한 주식 부여입니다. 이 보고는 내부자와 주주 간의 지속적인 일치를 나타내지만 기존 소유자에게는 소량의 희석 효과가 있습니다.

Points clés du Formulaire 4 pour SELECT MEDICAL HOLDINGS CORP (SEM) : Le Vice-Président Exécutif Martin F. Jackson s'est vu attribuer 150 000 actions ordinaires SEM le 29/07/2025. Ces actions sont des actions restreintes qui seront acquises en trois tranches annuelles égales (selon la note de bas de page) et ont été émises à un prix déclaré de 0 $, indiquant une incitation en actions plutôt qu'un achat sur le marché libre.

Suite à cette attribution, Jackson détient désormais 1 412 881 actions en direct. De plus, il déclare 10 536 actions détenues indirectement au bénéfice de ses enfants, dont il décline la propriété sauf pour tout intérêt pécuniaire.

Aucun titre dérivé n'a été déclaré dans le Tableau II et aucune vente n'a eu lieu, ce qui fait de cette opération une simple attribution d'actions. Ce dépôt signale un alignement continu des initiés avec les actionnaires, mais entraîne une légère dilution supplémentaire pour les propriétaires existants.

Formular 4 Highlights für SELECT MEDICAL HOLDINGS CORP (SEM): Der Executive Vice President Martin F. Jackson erhielt am 29.07.2025 150.000 Aktien der SEM-Stammaktien. Die Aktien sind eingeschränkte Aktien, die in drei gleichen jährlichen Tranchen (laut Fußnote) freigegeben werden und zu einem angegebenen Preis von 0$ ausgegeben wurden, was auf einen Aktienanreiz und nicht auf einen Kauf am offenen Markt hinweist.

Nach der Zuteilung hält Jackson nun 1.412.881 Aktien direkt. Zusätzlich meldet er 10.536 Aktien, die indirekt zugunsten seiner Kinder gehalten werden, für die er außer einem finanziellen Interesse auf die Verfügungsgewalt verzichtet.

In Tabelle II wurden keine derivativen Wertpapiere gemeldet und es fanden keine Verkäufe statt, sodass die Transaktion ausschließlich eine Aktienzuteilung darstellt. Die Meldung signalisiert eine weiterhin enge Ausrichtung der Insider mit den Aktionären, bringt jedoch eine geringe zusätzliche Verwässerung für die bestehenden Eigentümer mit sich.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
JACKSON MARTIN F

(Last) (First) (Middle)
C/O SELECT MEDICAL HOLDINGS CORPORATION
4714 GETTYSBURG ROAD

(Street)
MECHANICSBURG PA 17055

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SELECT MEDICAL HOLDINGS CORP [ SEM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EXECUTIVE VICE PRESIDENT
3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/29/2025 A(1) 150,000 A $0 1,412,881 D
Common Stock 2,634 I By son(2)
Common Stock 2,634 I By son(2)
Common Stock 2,634 I By daughter(2)
Common Stock 2,634 I By son(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Grant of restricted stock which will vest in equal annual installments over three years.
2. The reporting person beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
/s/ Michael E. Tarvin, Attorney-in-Fact 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many SEM shares did EVP Martin F. Jackson receive?

He was granted 150,000 restricted shares on 07/29/2025.

What is the vesting schedule for the new SEM restricted stock grant?

The shares vest in three equal annual installments over three years.

How many SEM shares does Jackson own after the transaction?

He directly owns 1,412,881 shares and indirectly reports 10,536 shares through family holdings.

Were any SEM shares sold in this Form 4 filing?

No. The filing only reports an award of restricted stock; there were no sales.

Does the Form 4 include any derivative securities like options or warrants?

Table II lists no derivative securities; the transaction involves common stock only.
Select Medical

NYSE:SEM

SEM Rankings

SEM Latest News

SEM Latest SEC Filings

SEM Stock Data

1.86B
110.06M
14.6%
83.81%
3.47%
Medical Care Facilities
Services-hospitals
Link
United States
MECHANICSBURG